ArticleFrontiers in endocrinology2026

Feminizing hormone therapy using GnRH agonists as antiandrogens is not associated with adverse metabolic and bone effects in adult transgender women.

Louise Brunet et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.